About Blackrock Health Sciences Trust (NYSE:BME)
BlackRock Health Sciences Trust is a non-diversified, closed-end management investment company (the Trust). The Trust's investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry. The Trust seeks to invest in a portfolio of equity securities and utilizing an option over-writing strategy in an effort to seek total return performance and enhance distributions. It invests in various industries, such as biotechnology, healthcare providers and services, diversified consumer services, pharmaceuticals, healthcare equipment and supplies, and life sciences tools and services sectors. BlackRock Advisors, LLC is the manager of the Trust.
Industry, Sector and Symbol
Industry Closed End Funds
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Blackrock Health Sciences Trust (NYSE:BME) Frequently Asked Questions
What is Blackrock Health Sciences Trust's stock symbol?
Blackrock Health Sciences Trust trades on the New York Stock Exchange (NYSE) under the ticker symbol "BME."
How often does Blackrock Health Sciences Trust pay dividends? What is the dividend yield for Blackrock Health Sciences Trust?
Blackrock Health Sciences Trust announced a monthly dividend on Monday, March 5th. Stockholders of record on Thursday, March 15th will be paid a dividend of $0.20 per share on Thursday, March 29th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 7.04%. The ex-dividend date is Wednesday, March 14th. View Blackrock Health Sciences Trust's Dividend History.
Who are some of Blackrock Health Sciences Trust's key competitors?
Some companies that are related to Blackrock Health Sciences Trust include Eaton Vance Floating-Rate Income Trust (EFT), Clearbridge Energy MLP Total Return Fund (CTR), MFS Charter Income Trust (MCR), Goldman Sachs MLP Inc Opp (GMZ), Carador Income Fund (CIFU), Oxford Lane Capital (OXLC), Center Coast Brookfield MLP&Enrg Inf Fnd (CEN), Kayne Anderson Energy Development (KED), BlackRock LT Municipal Advantage Trust (BTA), Voya Asia Pacific High (IAE), Malaysia Fund (MAY), Full Circle Capital (FULL), GLI Finance (GLIF), Andalas Energy and Power (ADL), Helios Advantage Income Fund (HAV), MCG Capital (MCGC) and Warehouse REIT (WHR).
Who are Blackrock Health Sciences Trust's key executives?
Blackrock Health Sciences Trust's management team includes the folowing people:
- Richard E. Cavanagh, Independent Chairman of the Board of Trustee (Age 72)
- John M. Perlowski, President, Chief Executive Officer, Trustee (Age 54)
- Karen P. Robards, Independent Vice Chairman of the Board of Trustees (Age 68)
- Neal J. Andrews, Chief Financial Officer (Age 52)
- Charles Park J.D., Chief Compliance Officer and Anti- Money Laundering Officer (Age 51)
- Robert W. Crothers, Vice President (Age 37)
- Jay M. Fife, Treasurer (Age 48)
- Janey Ahn, Secretary (Age 43)
- Michael J. Castellano, Independent Trustee (Age 72)
- Frank J. Fabozzi CPA, Independent Trustee (Age 70)
Has Blackrock Health Sciences Trust been receiving favorable news coverage?
News coverage about BME stock has been trending somewhat positive this week, Accern reports. The research group rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Blackrock Health Sciences Trust earned a coverage optimism score of 0.21 on Accern's scale. They also gave media stories about the company an impact score of 46.18 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Blackrock Health Sciences Trust's major shareholders?
Blackrock Health Sciences Trust's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include First Allied Advisory Services Inc. (0.37%), Ladenburg Thalmann Financial Services Inc. (0.26%), Advisor Group Inc. (0.15%) and BB&T Securities LLC (0.13%). Company insiders that own Blackrock Health Sciences Trust stock include Alexander Tsakumis and Gary Gordon Cope. View Institutional Ownership Trends for Blackrock Health Sciences Trust.
Which major investors are buying Blackrock Health Sciences Trust stock?
BME stock was acquired by a variety of institutional investors in the last quarter, including Ladenburg Thalmann Financial Services Inc., Advisor Group Inc., BB&T Securities LLC and First Allied Advisory Services Inc.. Company insiders that have bought Blackrock Health Sciences Trust stock in the last two years include Alexander Tsakumis and Gary Gordon Cope. View Insider Buying and Selling for Blackrock Health Sciences Trust.
How do I buy shares of Blackrock Health Sciences Trust?
Shares of BME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Blackrock Health Sciences Trust's stock price today?
One share of BME stock can currently be purchased for approximately $34.10.
How big of a company is Blackrock Health Sciences Trust?
Blackrock Health Sciences Trust has a market capitalization of $328.67 million.
How can I contact Blackrock Health Sciences Trust?
Blackrock Health Sciences Trust's mailing address is 100 Bellevue Pkwy, WILMINGTON, DE 19809-3700, United States. The company can be reached via phone at +1-800-8820052.
MarketBeat Community Rating for Blackrock Health Sciences Trust (BME)MarketBeat's community ratings are surveys of what our community members think about Blackrock Health Sciences Trust and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Blackrock Health Sciences Trust (NYSE:BME) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Earnings History for Blackrock Health Sciences Trust (NYSE:BME)
No earnings announcements for this company have been tracked by MarketBeat.com
Blackrock Health Sciences Trust (NYSE:BME) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Blackrock Health Sciences Trust (NYSE:BME) Dividend Information
|Dividend Growth:||10.10% (3 Year Average)|
Blackrock Health Sciences Trust (NYSE:BME) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Blackrock Health Sciences Trust (NYSE BME) Insider Trading and Institutional Ownership History
Blackrock Health Sciences Trust (NYSE BME) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|8/15/2017||Gary Gordon Cope||Director||Sell||700,000||$0.57||$399,000.00|
|6/6/2017||Gary Gordon Cope||Director||Buy||8,500||$0.64||$5,440.00|
|6/5/2017||Gary Gordon Cope||Director||Buy||11,500||$0.66||$7,590.00|
|5/15/2017||Gary Gordon Cope||Director||Buy||9,000||$0.90||$8,100.00|
|5/2/2017||Gary Gordon Cope||Director||Buy||2,000||$0.98||$1,960.00|
|2/9/2017||Gary Gordon Cope||Director||Buy||400||$1.40||$560.00|
|2/2/2017||Gary Gordon Cope||Director||Sell||200,000||$1.45||$290,000.00|
|11/7/2016||Gary Gordon Cope||Director||Buy||10,000||$0.90||$9,000.00|
|3/28/2016||Gary Gordon Cope||Director||Buy||24,500||$0.17||$4,165.00|
|3/25/2016||Gary Gordon Cope||Director||Buy||1,000||$0.17||$170.00|
|3/24/2016||Gary Gordon Cope||Director||Buy||1,000||$0.17||$170.00|
|3/23/2016||Gary Gordon Cope||Director||Buy||80,500||$0.17||$13,685.00|
|3/22/2016||Gary Gordon Cope||Director||Buy||24,000||$0.17||$4,080.00|
|1/27/2016||Gary Gordon Cope||Director||Buy||3,000||$0.08||$240.00|
|1/26/2016||Gary Gordon Cope||Director||Buy||44,000||$0.09||$3,740.00|
|1/25/2016||Gary Gordon Cope||Director||Buy||6,000||$0.09||$510.00|
|1/14/2016||Gary Gordon Cope||Director||Buy||54,500||$0.10||$5,450.00|
|11/19/2015||Gary Gordon Cope||Director||Buy||5,000||$0.14||$675.00|
|10/28/2015||Gary Gordon Cope||Director||Buy||1,500||$0.10||$150.00|
|10/27/2015||Gary Gordon Cope||Director||Buy||3,000||$0.13||$390.00|
|10/1/2015||Gary Gordon Cope||Director||Buy||15,000||$0.10||$1,500.00|
Blackrock Health Sciences Trust (NYSE BME) News Headlines
Blackrock Health Sciences Trust (NYSE:BME) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Blackrock Health Sciences Trust (NYSE BME) Stock Chart for Friday, March, 23, 2018